TIDMYGEN

Yourgene Health PLC

28 November 2019

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Opening of New Facilities and Corporate HQ

Manchester, UK - 28 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its newly integrated facilities and corporate HQ at Citylabs 1.0, in the centre of Manchester's genomics campus, and continued expansion with a planned further increase in headcount at the Company's UK headquarters.

The establishment of the new Company head office at Citylabs 1.0, Nelson Street, Manchester, M13 9NQ, in the centre of Manchester's genomics campus, is part of the ongoing integration of the Elucigene acquisition which completed in April 2019. Citylabs is based on a joint venture partnership between Manchester Science Partnerships, the UK's leading science and technology park operator, and Manchester University NHS Foundation Trust, the UK's largest NHS provider Trust, and is the only development of its kind in the UK. The Citylabs campus, currently undergoing a GBP95m expansion, is surrounded by Manchester's leading hospitals and makes it part of Europe's largest clinical-academic campus.

Following the acquisition of Elucigene, all departments are being combined into a single management structure and manufacturing concentrated onto the one site and the new facility is already generating a strong cultural alignment across the enlarged Group. Plans for process, systems and regulatory harmonisation are well advanced and will be completed by the end of the financial year in March 2020.

Yourgene Health currently employs 125 staff around the world, with 89 staff now based at the enlarged UK headquarters in Manchester. The Company has aspirations to grow staff numbers to support the business growth anticipated over the next few years. The Company is currently recruiting new staff in Manchester and has opportunities for talented individuals with relevant scientific backgrounds and commercial experience: https://www.yourgene-health.com/contact-us/recruitment

Lyn Rees, CEO of Yourgene Health plc, said: "I am delighted at the progress we've made to integrate the Elucigene acquisition, and the opening of our new facilities and HQ at Citylabs, in the heart of Manchester's exciting genomics hub, marks a new stage of growth for our business. Together we have cultivated a dynamic fast-paced culture offering a great opportunity to work with class leading products and be part of developing and commercialising the next generation of products to improve patient health globally. Citylabs provides us with world-class facilities to operate from and a vibrant place to work for our team."

 
Yourgene Health plc                                                   Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                               investors@yourgene-health.com 
 Barry Hextall, Chief Financial Officer 
 Joanne Cross, Director of Marketing 
 
Stifel Nicolaus Europe Limited (Sole                                  Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
 Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
Walbrook PR Ltd (Media and Investor        Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations)                                              Mob: 07980 541 893 Mob: 07584 391 303 
 Paul McManus / Lianne Cawthorne

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUBAARKNAAUUA

(END) Dow Jones Newswires

November 28, 2019 02:01 ET (07:01 GMT)

Premaitha (LSE:NIPT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Premaitha.
Premaitha (LSE:NIPT)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Premaitha.